Now Taking Pre-Orders

Be One of the First to Own
4BK BioKey

Revolutionary health technology starts with those bold enough to be first. Pre-order members receive priority shipping, exclusive early-adopter status, and direct access to Billy Carson's wellness community.

What you get with your pre-order:

60+ biomarkers detected from one breath in 15 seconds
AI-powered personalized health insights and trend tracking
Built-in OLED display - no smartphone required
100+ tests per charge via USB-C fast charging
Patent Pending technology (No. 63/957,003)
Free worldwide shipping - no hidden fees
Early-adopter exclusive community access
4BK BioKey Device

Retail $599

$444

Free Shipping Worldwide

Limited Pre-Order Pricing

Secure checkout powered by Stripe

100% money-back guarantee

Patent Pending · Raising $5M Seed Round

4BK BioKeyThe Breath of Knowledge

The world's first consumer-grade modular breathomics platform, detecting 60+ biomarkers from a single breath to unlock your body's hidden metabolic intelligence.

"A paradigm shift in how humanity monitors and optimizes health." - Billy Carson, Founder & CEO

4BK BioKey Device
1000+
VOCs Detectable
in a single breath
60+
Target Biomarkers
clinically validated
85%
Accuracy
cirrhosis detection vs. biopsy
$110M
Projected Revenue
by Year 5 (2030)

Engineering Excellence

12 integrated subsystems in a compact handheld form factor. Precision sensor integration and intelligent airflow management.

60+ Biomarkers Detected

Modular sensor array via MOS, NDIR, and electrochemical sensing platforms detects over 20 clinically validated molecular signatures.

Real-Time Metabolic Monitoring

Instant results in 15 seconds. Metabolic Index (0-100), acetone concentration in ppm, and trend direction from a single breath.

AI-Powered Personalization

Adaptive baseline modeling learns your unique biomarker range over 14 days. Pattern recognition engine and natural language coaching insights.

Comprehensive Health Detection

Detects markers for metabolic disorders, respiratory conditions, GI disorders, hepatic function, cardiovascular risk, and neurological indicators.

HIPAA & GDPR Compliant

End-to-end AES-256 encryption with SOC 2 Type II certification pathway and optional local-only privacy mode.

100+ Tests Per Charge

3.7V 1200mAh lithium-ion battery. USB-C fast charging. 30-day standby. OLED display shows results without needing a smartphone.

Comprehensive Disease Detection

Analyzing breath biomarkers across 7 major disease categories, grounded in peer-reviewed research and clinical validation.

Metabolic & Nutritional

  • Diabetes Mellitus
  • Ketoacidosis Monitoring
  • Hypercholesterolemia
  • Urea Cycle Disorders

Respiratory & Inflammatory

  • Asthma Management (FeNO)
  • COPD Monitoring
  • Infection Detection
  • Airway Inflammation

Gastrointestinal

  • SIBO Diagnosis
  • Food Intolerance Testing
  • H. pylori Infection
  • Gut Microbiome Health

Cardiovascular

  • Ischemic Detection
  • Oxidative Stress Assessment
  • Hypertension Monitoring
  • Cardiac Risk Profiling

Neurological

  • Alzheimer's Markers
  • Parkinson's Indicators
  • Hepatic Encephalopathy
  • Cognitive Decline Tracking

Oncological (Emerging)

  • Lung Cancer VOC Signatures
  • Breast Cancer Markers
  • Colorectal Screening
  • Pancreatic & Liver Indicators
Patent Pending

Intellectual Property Protected

A Provisional Patent Application (No. 63/957,003) has been filed with the U.S. Patent and Trademark Office in the name of Mr. Billy Carson. Filed January 9, 2026.

First-to-market consumer breathomics platform
18-24 month lead over potential competitors
510(k) clearance pathway creates regulatory moat
Patent portfolio development underway
Patent Pending Certificate

Modular Expansion Roadmap

Four phases of sensor expansion targeting progressively larger healthcare markets.

Phase 1 · Active

Core Platform

Acetone, isoprene, CO2, basic VOC array for metabolic wellness. Consumer launch configuration.

Phase 2

FeNO Module

Electrochemical NO sensor for asthma/COPD management. FDA 510(k) pathway.

Phase 3

GI Module

H2/CH4 sensors for SIBO and food intolerance testing. Expands into gastroenterology.

Phase 4

Advanced VOC

Enhanced aldehyde and sulfur compound detection for infection and cancer screening research.

Investment Opportunity

$5M Series Seed Round

Join Billy Carson in commercializing the next generation of non-invasive health diagnostics. Target close: Q1 2026.

1380%
Simple 5-Year ROI
88%
Internal Rate of Return
$372M-$465M
Exit Valuation Potential
14.8-18.6x
Return on 20% Equity Stake
"The 4BK BioKey represents the convergence of ancient breathwork wisdom and cutting-edge biosensor technology, a paradigm shift in how humanity monitors and optimizes health."

Billy Carson, Founder & CEO

Commercial launch Q2 2026
Breakeven Q3 2027 | Cash Positive Q1 2028
5-Year cumulative net profit: $74 Million
Projected exit valuation: $372M-$465M by 2030
Seed investors: 14.8-18.6x return on 20% equity

Complete the secure form to receive the full investor deck and schedule a call.

Frequently Asked Questions

Be Part of the Health Revolution

The 4BK BioKey is not just a device. It is a platform that bridges ancient wisdom and modern biosensor science. Secure your position as a seed investor today.

Provisional Patent Application No. 63/957,003 · Filed January 9, 2026 · 4BiddenKnowledge Inc.